Fc Heterodimer Proteins Asymmetric Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing bispecific therapeutics face challenges in selectively forming heterodimeric Fc chain pairs, leading to reduced stability and increased costs due to non-selective formation of unwanted Fc chain pairs, which affects manufacturing, stability, and pharmacokinetic properties.
Innovation Solution
The development of Fc heterodimer proteins in crystalline form using specific amino acid sequences and structural modifications that promote heterodimeric Fc chain pair formation, combined with a mother liquor solution containing ethylene glycol and polyethylene glycol, to achieve high purity and stability while maintaining wild-type-like properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective co-expression of four different antibody chains is used, then bispecific antibody production is achieved, but formation of unwanted homodimers occurs reducing heterodimer yield to maximum 12.5%
Solution Approach 1:
The patent applies asymmetry by introducing different amino acid mutations at the CH3-CH3 interface of the two heavy chains (e.g., L351Y in one chain and L351F in the other), creating non-equivalent binding surfaces that drive selective heterodimer formation while preventing homodimerization, thereby increasing heterodimer yield from 12.5% to over 95%
Solution Approach 2:
The patent modifies only the local CH3-CH3 interface region with specific amino acid substitutions (such as L351Y/L351F, T366S/T366W) while leaving the rest of the antibody structure unchanged, enabling selective heterodimer formation without affecting overall antibody functionality or requiring complete redesign of the molecular scaffold
2Reliability
If knob-into-hole steric point mutations are employed to drive heterodimerization, then heterodimer selectivity is improved, but thermal stability of the CH3 domain decreases by about 11°C
Solution Approach 1:
The patent changes the chemical parameters of the CH3-CH3 interface by introducing aromatic amino acids (tyrosine Y399, phenylalanine F405, tryptophan W394) that form pi-stacking and hydrophobic interactions, providing both heterodimer selectivity and thermal stability without the 11°C stability loss associated with traditional knob-into-hole mutations
Solution Approach 2:
The patent creates a composite interface combining multiple interaction types: aromatic pi-stacking (Y399, F405, W394), hydrophobic interactions (L351Y/L351F), and hydrogen bonding (Q311, N312), which together provide both selective heterodimer formation and maintained thermal stability, overcoming the limitation of single-mechanism approaches
3Reliability
If electrostatic complementarity design strategy is used, then selective heterodimerization is achieved, but melting temperature of the CH3 domain decreases to approximately 68°C
Solution Approach 1:
The patent modifies the electrostatic and hydrophobic parameters at the CH3-CH3 interface by introducing aromatic residues (Y399, F405, W394) and hydrophobic mutations (L351Y/L351F), creating a interface that provides both selective heterodimerization and enhanced thermal stability with melting temperature above 75°C, overcoming the 68°C limitation of pure electrostatic designs
4Manufacturing precision
If mutations in the Fc region are introduced to prevent homodimer formation, then heterodimer purity is improved, but manufacturing costs increase due to reduced stability
Solution Approach 1:
The patent enables self-service by designing mutations (L351Y/L351F, T366S/T366W, Y399, F405, W394) that create intrinsic self-association preferences for heterodimer formation through complementary shape and chemical properties, allowing the protein to self-sort into heterodimers during expression and purification without requiring external selection pressures or complex manufacturing processes, thereby reducing costs while achieving over 95% purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach achieves over 99% purity of heterodimeric Fc proteins with wild-type-like stability and pharmacokinetic properties, reducing manufacturing costs and ensuring favorable drug-like characteristics such as stability and immunogenicity.
Implementation Method 1
The development of Fc heterodimer proteins in crystalline form using specific amino acid sequences and structural modifications that promote heterodimeric Fc chain pair formation, combined with a mother liquor solution containing ethylene glycol and polyethylene glycol
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are the atomic coordinates of compositions comprising Fc heterodimer proteins in crystalline form derived from high resolution x-ray diffraction. Further disclosed are systems and methods for using all or a portion of these atomic coordinates to identify and design improved Fc heterodimer proteins. Further disclosed are compositions comprising a mixture of (i) a solubilized Fc heterodimer protein and (ii) a mother liquor solution. The mother liquor solution comprises between 2% and 10% (v/v) ethylene glycol, between 10% and 25% (w/v) polyethylene glycol having an average molecular weight of between 2000 Daltons and 10000 Daltons, and between 0.05 M and 0.40 M ammonium iodide. Further disclosed are systems and methods of identifying a mutation which promotes heterodimeric Fc chain pair formation in which structure based modeling is performed to identify a candidate mutation to an Fc chain using all or a portion of the disclosed three-dimensional atomic coordinates.